The CD47 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian carcinoma cell line. This product features a targeted disruption of the CD47 gene using CRISPR/Cas9-mediated gene editing, generating a heterogeneous pool of cells with loss-of-function modifications in the CD47 locus. The polyclonal format provides a versatile model for studying CD47-dependent mechanisms in a mixed cellular background, avoiding clonal bias and retaining the genetic diversity inherent to the parental line.
The A2780 cell line is an epithelial ovarian cancer cell line established from an untreated patient, widely employed as a model for ovarian carcinoma. Its well-characterized sensitivity to chemotherapeutic agents and its relevance to high-grade serous ovarian cancer make it a valuable platform for drug sensitivity studies and preclinical evaluation of novel therapeutics. The A2780 line retains key oncogenic pathways and serves as a standard in vitro system for ovarian cancer research.
CD47 encodes a cell surface receptor that serves as a ‘don’t eat me’ signal by binding SIRP?? on macrophages, which triggers recruitment of SHP-1 and SHP-2 phosphatases and inhibits myosin-II assembly, thereby suppressing phagocytosis. Its expression is transcriptionally regulated by HIF-1??, MYC, NF-??B, and inflammatory cytokines. CD47 also interacts with integrins (??v??3, ??IIb??3), thrombospondin-1, and VEGFR2, connecting it to integrin signaling and cell adhesion pathways.
In the A2780 ovarian cancer context, CD47 disruption allows investigation of immune evasion mechanisms. Overexpression of CD47 in ovarian tumors contributes to immune escape and poor prognosis; knockout in this cell line provides a model to study how loss of anti-phagocytic protection enhances macrophage-mediated clearance, alters drug sensitivity, and may influence integrin-mediated adhesion and migration. This polyclonal population enables assessment of heterogeneous tumor cell responses under immune pressure.
Researchers can utilize these CD47 knockout A2780 polyclonal cells in macrophage co-culture phagocytosis assays, ADCP reporter systems, and flow cytometry to confirm CD47 ablation. They are applicable to in vivo xenograft models for tumor growth and immune infiltration studies, and to drug resistance experiments evaluating interactions with chemotherapeutics. Western blotting can reveal changes in downstream SHP-1/SHP-2 signaling. For further details, contact Ascent Research.
